Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rezafungin Acetate

FDA-approved product (powder, intravenous), marketed as Rezzayo.

Registered studies
5
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rezafungin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Candidemia
  • Candidiasis
  • Candidiasis, Invasive

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antimycotics for systemic use
FDA pharmacologic class
Echinocandin Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX08; FDA class Echinocandin Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

5registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rezafungin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rezafungin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

    NCT06794554 · start 2025-06-30

    Registered record
    Registry ID
    NCT06794554
    Conditions
    Chronic Pulmonary Aspergillosis
    Interventions
    Rezafungin Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-06-30
    Completion
    2026-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Pulmonary Aspergillosis
    InterventionRezafungin Acetate
    PhasePhase 2
    Registry statusActive not recruiting

  • Rezafungin Pharmacokinetics in Patients on ECMO

    NCT06329518 · start 2024-07-01

    Registered record
    Registry ID
    NCT06329518
    Conditions
    Sepsis
    Interventions
    Rezafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2024-07-01
    Completion
    2024-12-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionRezafungin
    PhasePhase 1
    Registry statusWithdrawn

  • Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

    NCT05835479 · start 2023-11-14

    Registered record
    Registry ID
    NCT05835479
    Conditions
    Pneumocystis Pneumonia
    Interventions
    Co-Trimoxazole; Rezafungin Acetate / Co Trimoxazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-11-14
    Completion
    2025-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumocystis Pneumonia
    InterventionCo-Trimoxazole; Rezafungin Acetate / Co Trimoxazole
    PhasePhase 2
    Registry statusRecruiting

  • Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age

    NCT05534529 · start 2023-09-13

    Registered record
    Registry ID
    NCT05534529
    Conditions
    Invasive Fungal Infections
    Interventions
    Rezafungin Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2023-09-13
    Completion
    2024-10-14
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infections
    InterventionRezafungin Acetate
    PhasePhase 1
    Registry statusTerminated

  • Safety and Pharmacokinetics of Rezafungin

    NCT04117607 · start 2019-12-04

    Registered record
    Registry ID
    NCT04117607
    Conditions
    Fungal Infection
    Interventions
    Placebo; Rezafungin; Rezafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2019-12-04
    Completion
    2020-05-11
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Infection
    InterventionPlacebo; Rezafungin; Rezafungin
    PhasePhase 1
    Registry statusTerminated